Regent Pacific Group Limited announced several key findings on the willingness of payers in the United States to cover Fortacin™ and the level of price sensitivity for coverage carried out by a leading global third-party marketing consultant to further its recent payer research by building out the US market landscape, price sensitivity and reimbursement expectations for both payer coverage and adding patients' out-of-pocket expenses (or copay) sensitivity. The marketing consultant conducted in-depth telephone interviews with payers who cover erectile dysfunction ("ED") drugs on formulary and payers who cover ED drugs through a rider. Summary of the research are as follows: Payers see Fortacin™ as a novel product, with good efficacy and expect there will be employer-based group demand for coverage; Entry price level of Fortacin™ for the US market is over USD 144 per 12 dose can/unit, exceeding the Group's expectation by 4 times for the US market and 1.5 times higher than the expected and currently modelled price by which Wanbang Pharmaceutical Marketing and Distribution Co. Ltd., the Company's commercial strategic partner for China expects to receive in China as compared to the current price for a 12 dose can in Europe and the UK; 52.4% of lives (83% of plans) would cover Fortacin™ with or without a rider at all price points; Payers kept their type of coverage consistent, such that plans covering ED drugs on formulary said Fortacin™ would be covered the same as the current drugs on formulary versus ED drugs through rider (i.e. Fortacin™ä through a rider). The Group has engaged the third-party marketing consultant to further its recent payer research and it will provide further recommendations on pricing, reimbursement and market access expectations. It is expected that the recommendations will be available to the Group by May 2021 and assist with negotiations with potential US commercial strategic partners.